Tanuk Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 8.50 Cr
as on 15-11-2024
- Paid Up Capital ₹ 3.67 Cr
as on 15-11-2024
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.05 Cr
as on 15-11-2024
- Satisfied Charges ₹ 6.00 Cr
as on 15-11-2024
- Revenue 4.91%
(FY 2023)
- Profit 99.62%
(FY 2023)
- Ebitda 99.46%
(FY 2023)
- Net Worth -0.00%
(FY 2023)
- Total Assets -0.32%
(FY 2023)
About Tanuk Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.50 Cr and a paid-up capital of Rs 3.67 Cr.
The company currently has active open charges totaling ₹1.05 Cr. The company has closed loans amounting to ₹6.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kidar Bhalla, Pankaj Thakur, and Lokesh Saxena serve as directors at the Company.
- CIN/LLPIN
U74899DL1995PLC065899
- Company No.
065899
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Feb 1995
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tanuk Pharma (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kidar Bhalla  | Director | 28-Feb-1995 | Current |
| Pankaj Thakur | Director | 10-Aug-2016 | Current |
| Lokesh Saxena | Additional Director | Current |
Financial Performance and Corporate Structure Insights of Tanuk Pharma (India).
Tanuk Pharma (India) Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.91% increase. The company also saw a substantial improvement in profitability, with a 99.62% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tanuk Pharma (India)?
In 2023, Tanuk Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Surya Pharma And Herbal Private LimitedInactive For E-Filing 20 years 10 monthsKidar Bhalla is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Housing Development Finance Corporation Limited Creation Date: 31 Mar 2015 | ₹7.00 M | Open |
Standard Chartered Bank Creation Date: 19 Sep 2011 | ₹3.45 M | Open |
Bank Of Baroda Creation Date: 16 May 2014 | ₹3.25 Cr | Satisfied |
How Many Employees Work at Tanuk Pharma (India)?
Unlock and access historical data on people associated with Tanuk Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tanuk Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tanuk Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
